Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 12, 2026

Trump tariffs live updates: US explores new tariffs in investigation targeting trading partners

View original at finance.yahoo.com
Trump tariffs live updates: US explores new tariffs in investigation targeting trading partners The US is pursuing new tariffs on nations with which it trades, pivoting after the Supreme Court struck down President Trump's most sweeping tariffs under the International Emergency Economic Powers Act (IEEPA)…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Customs agency cannot comply with federal judge's order to automatically refund importers' tariff payments without their requesting the refunds

    60% confidence

  • Trump administration's tariff refund delay is theft in broad daylight

    60% confidence

  • Electronic refund process will be ready within 45 days

    60% confidence

  • 15% global tariff could begin sometime this week

    60% confidence

  • US businesses and consumers have paid for tariffs, pushing up inflation

    60% confidence

  • US economic growth was muted in February as tariffs increased costs for businesses, some of which passed along higher prices to consumers

    60% confidence

  • Importers would receive only one payment from Treasury Department, regardless of how many items or declarations they filed

    60% confidence

Data points we hold from this source

Donald Trump · tariff revenue decline1 USD
Donald Trump · planned global tariff rate15 percent
Donald Trump · current global tariff rate10 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Trump tariffs live updates: US explores new tariffs in investigation targeting trading partners — Source | Via News | ViaNews EU